

ACURA PHARMACEUTICALS, INC

Form 8-K

October 16, 2014

UNITED STATES

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D. C. 20549**

FORM 8-K

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act Of 1934**

**October 16, 2014**

Date of Report (Date of earliest event reported)

**ACURA PHARMACEUTICALS, INC.**

(Exact Name of Registrant as Specified in Charter)

**State of New York**

(State of Other Jurisdiction  
of Incorporation)

**1-10113**

(Commission File Number)

**11-0853640**

(I.R.S. Employer  
Identification Number)

Edgar Filing: ACURA PHARMACEUTICALS, INC - Form 8-K

616 N. North Court, Suite 120

Palatine, Illinois 60067

(Address of principal executive offices) (Zip Code)

**(847) 705-7709**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))

**Item 8.01 Other Events**

On October 16, 2014 we issued a press release regarding the US Food and Drug Administration's (FDA) denial on procedural grounds of our appeal of the position taken by Division of Anesthesia, Analgesia, and Addiction Products (DAAAP) of the FDA that abuse by snorting of hydrocodone with acetaminophen products lacks relevance.

The press release is attached hereto and filed as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits**

**Exhibit Number Description**

99.1	Press Release dated October 16, 2014
------	--------------------------------------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**ACURA PHARMACEUTICALS, INC.**

By: /s/ Peter A. Clemens  
Peter A. Clemens  
Senior Vice President & Chief Financial Officer

Date: October 16, 2014

**Exhibit Index**

**Exhibit Number Description**

99.1 Press Release dated October 16, 2014